- INmune
Bio’s IPO closed February 1, 2019, with NASDAQ Capital Markets listing on
February 4, 2019
- Public
clinical-stage immunology company with programs in oncology and
neurodegenerative disease
- INmune
Bio targets large markets with unsolved problems such as resistance to
checkpoint inhibitor therapy, a fast-growing oncology market segment; MRD,
the cause of cancer relapse; and neuroinflammation as a cause of
Alzheimer’s disease
- Receiver
of “Part the Cloud” $1 million grant awarded by Alzheimer’s Association
- Experienced
leadership with extensive experience in the targeted fields of clinical
research and drug development
- Intellectual
property with multiple filings in process for INB03/XPro1595 and INKmune
- Insider
led round at $9 per share for approximately $4.6 million in May
INmune Bio Inc. (NASDAQ: INMB) is a diversified
clinical-stage immunology company developing novel therapies that target
distinct parts of a patient’s innate immune system to fight disease. Drug
candidates
INKmune and
INB03 may be used to treat
cancer while
XPro1595 targets neuroinflammation as a cause of
Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy
approach to promote the body’s innate immune response to treat unsolved
problems in medicine.
INmune Bio is the first biotechnology company to close an
initial public offering (IPO) in 2019 and commence trading on The Nasdaq
Capital Market. The company also received a “Part the Cloud” award from the
Alzheimer’s Association in 2018 which included a $1 million grant to advance
INmune Bio’s XPro1595 drug candidate.
INmune Bio’s product pipeline targets three segments of
concern:
- Alzheimer’s
disease/dementia claims 5.5 million patients in the United States. INmune
Bio views Alzheimer’s as an immunologic disease which changes the drug
discovery process, changes the way clinical trials are designed, and may
provide hope for patients and caregivers.
- Cancer
residual disease which is expected to generate more than 1.7 million new
cases yearly with an estimated 609,640 fatalities. INMB believe that
converting resting Natural Killer (“NK”) cells to primed NK cells, which
kill cancerous cells on contact, is an important therapeutic strategy to
help clear residual disease.
- Resistance
to immunotherapy. By preventing the proliferation and function of cells
that resist immunotherapy, patients should have a stronger immune response
to cancer cells and may respond better to other cancer treatments
including immunotherapy and live longer.
INmune Bio Drug Candidates and Clinical Programs
INKmune is a biologic delivery system that primes a
patient’s resting NK cells to kill cancer. INKmune targets residual disease for
patients that have completed initial cancer therapy (surgery, radiation and/or
chemotherapy) and have a low burden of disease with a high risk of relapse.
In late 2019, INKmune will start enrolling patients in a
phase I/II trial for women with relapsed refractory ovarian cancer. In many
patients, cancer relapse after seemingly effective cancer therapy is due to a
failure of the patients own NK cells to eliminate minimal residual disease
(“MRD”).
Using a novel mechanism of action and a precision medicine
approach, INKmune therapy should enhance NK cells’ ability to eliminate
residual disease.
INB03 is a checkpoint inhibitor that targets myeloid
derived suppressor cells (“MDSC”) which can produce an immunosuppressive shield
that prevents a patient’s own immune system from attacking the cancer. INmune
Bio is currently completing a monotherapy INB03 phase I trial in patients with
advanced solid tumors. The INB03 program will transition into a combination
therapy clinical program in the summer of 2019 to prepare for a phase II trial
in patients resistant to checkpoint inhibitors due to increased MDSC.
Treatment with INB03 should eliminate MDSC in the tumor
microenvironment to allow checkpoint inhibitors to be therapeutically
effective.
XPro1595 targets the microglial immune cells of the
brain that are activated in many Alzheimer’s disease patients. These microglial
cells are a cause of neuroinflammation that can kill nerve cells and promote
synaptic dysfunction – the cause of dementia in Alzheimer’s.
The three-month, phase I trial is expected to enroll 18
patients in summer of 2019. It is designed to measure traditional and novel
biomarkers of inflammation in patients with mild to moderate Alzheimer’s
disease who have neuroinflammation. The trial is supported by a $1 million
“Part the Cloud” grant from the Alzheimer’s Association. Inflammation, especially
chronic inflammation, is being recognized as an important part of the pathology
of many diseases including cancer and Alzheimer’s disease.
Management
Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting
chief medical officer, has been a licensed physician since 1982 and a Fellow of
the American College of Surgery since 1991. He received his medical degree from
Washington University School of Medicine in 1982 and has served many roles in
several development-stage biotech companies focused on treatment of
neurodegenerative diseases, hematologic malignancies, and other inflammatory
diseases.
CFO David J. Moss, co-founder, has been with the company
since its formation in September 2015. He holds an MBA from Rice University and
a bachelor’s degree in economics from the University of California, San Diego.
Moss has founded, funded and taken public various companies in a variety of
industries since 1995.
Mark Lowdell, Ph.D. co-founder, has served as the chief
scientific officer and chief manufacturing officer at INmune Bio since the
company’s formation. He is a professor of cell and tissue therapy at University
College London where he has led a translational immunotherapy group since 1994.
He has also been a director of cellular therapy at the Royal Free London NHS
Foundation Trust. He received his Ph.D. in clinical immunology from London
Hospital Medical College, University of London in 1992 and is a qualified
immunopathologist.
Christopher J. Barnum is director of neuroscience at INmune
Bio. Barnum is a neuroimmunologist with broad expertise across
neurodegenerative and psychiatric diseases holding multiple positions in
academic and industry. His focus has been on translating inflammatory therapies
into clinical treatments for neurologic diseases using a biomarker-directed
approach. Barnum’s research has been supported by the NIH, the Michael J. Fox
Foundation, and the Alzheimer’s Association. He received his Ph.D. in
neuroscience from Binghamton University.
NOTE TO INVESTORS: The latest news and updates relating
to INMB are available in the company’s newsroom at
http://ibn.fm/INMB
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published:
http://www.missionir.com/disclaimer.html
